In its second earnings call as a public company, Livongo was able to report strong financial and operational numbers and raise its revenue guidance for the year from $7 million to $9.5 million. CEO Zane Burke also shared that the company's diversification beyond diabetes is making progress: more than 20% of the company's estimated value from new partnerships is from non-diabetes business.
TOPLINE...
